Lutetium in the treatment of neuroendocrine tumours

Lutetium-labelled peptides for therapy of neuroendocrine tumours

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3304065

Treatment with radiolabelled somatostatin analogues is a promising new tool in the management of patients with inoperable or metastasized neuroendocrine tumours. Symptomatic improvement may occur with 177Lu-labelled somatostatin analogues that have been used for peptide receptor radionuclide therapy (PRRT).